Metformin × BMI

Study 1 · Limited

Early use of effective therapies may improve diabetes outcomes

Comparison

Metformin as first line therapy, followed by empagliflozin 10 mg as second line therapy, and tirzepatide 10 mg as third line therapy. · Metformin as first line therapy, followed by empagliflozin 10 mg as second line therapy, and liraglutide 1.8 mg as third line therapy. · Metformin as first line therapy, followed by empagliflozin 10 mg as second line therapy, and semaglutide 1.0 mg as third line therapy. · Metformin as first line therapy, followed by empagliflozin 10 mg as second line therapy, and dulaglutide 3.0 mg as third line therapy.

Duration / follow-up

156 weeks

Study 2 · Limited

GLP-1 agonists reduce heart fat thickness in diabetes.

Comparison

Patients received semaglutide as part of their treatment regimen. · Patients received dulaglutide as part of their treatment regimen. · Patients received metformin as the control treatment.

Duration / follow-up

12 weeks

Study 3 · Included

Vildagliptin and Metformin Improve Glycemic Control in Type 2 Diabetes

Rct

Comparison

Patients received 50 mg of vildagliptin orally twice daily. · Patients received 500 mg of metformin orally twice daily with meals, with dosage adjustable.

Duration / follow-up

26 weeks